Business
Medicenna Announces March 31, 2020 Year-End Results
Medicenna Announces March 31, 2020 Year-End Results Canada NewsWire TORONTO and ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces March 31, 2020 Year-End Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, May 15, 2020\n\n\n\n-     End of Phase 2 meeting package for MDNA55 to be submitted in Q2 2020--     IND submission for IL-2 Superkine Platform calendar Q1 2021--     Two abstracts to be presented at ASCO 2020-\n TORONTO and HOUSTON, May 15, 2020 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company, today announced its operational and financial results for the year ended March 31, 2020.\n\"Fiscal 2020 was a year of considerable accomplishment on all fronts for Medicenna. We had promising non-human primate pre-clinical data with our IL-2 Superkine Platform, solid results from our Phase 2b clinical trial for MDNA55 and successful financings at higher prices than earlier offerings with gross proceeds of over $47 million establishing a solid balance sheet to meet our next set of milestones,\" said Dr. Fahar Merchant, President and CEO of Medicenna. \n\"We are well-positioned for continued success in calendar 2020 and 2021, as we plan to submit our end of phase 2 (EoP2) meeting package to the FDA this quarter, expect input from the agency in calendar Q3 and planned listing on Nasdaq calendar Q4. We also expect to complete our IND enabling studies for our MDNA109 Superkine Platform by Q1 of calendar year 2021\" adds Dr. Merchant. \"While we are proud of what we've achieved thus far, we believe that the best is yet to come.\"  \nProgram highlights for the year ended March 31, 2020, along with recent developments, include: \nMDNA55: Recurrent Glioblastoma Program \nOn April 30, 2019, completed enrolment in the MDNA55 Phase 2b clinical study for the treatment of recurrent glioblastoma (\"rGBM\").On June 3, 2019 a poster entitled \"MDNA55: A Locally Administered IL4 Guided Toxin as a Targeted Treatment for Recurrent GliMDNA11oblastoma\" was presented ...